Michael Hackett

Michael Hackett has worked in various roles within the biosciences industry since 2010. Michael began their career as Chief Scientific Officer (CSO) at NovoLipid in 2010. In 2011, they were a Post-doctoral Fellow at the University of North Carolina at Chapel Hill, followed by a Post-doctoral Researcher role at Seoul National University in 2013. In 2014, they became a Product Manager, DMPK, Bioanalysis, Toxicology at WuXi AppTec. From 2017 to 2020, they were a Principal Research Scientist at Battelle, and they are currently a Group Leader at Xencor since 2020. Most recently, in 2022, they were appointed Director of Toxicology at MBX Biosciences, Inc.

Michael Hackett received their B.S. in Biochemistry from Case Western Reserve University in 2006. Michael then went on to pursue a Ph.D. in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill, which they completed in 2011. Prior to this, they attended St. Xavier High School. In 2018, Michael obtained a DABT certification from the American Board of Toxicology, Inc.